Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor
Stockholm, Sweden – January 12, 2024 – Biosergen AB (“Biosergen” or the “Company”), a clinical-stage biotech company specializing in the development of innovative antifungal therapies, today announced a change in management from 31 January 2024 when Peder M. Andersen will step down from his current role as CEO and transition into a Chief Medical Officer role in Biosergen. The Board of Directors at Biosergen has appointed Tine Olesen as the new CEO from 1 February 2024 after serving as COO in Biosergen during the past two and half years. Peder M. Andersen has served as CEO of the company for